The EU Medical Device Regulation (MDR, EU 2017/745) defines the regulatory framework for the design, evaluation, and commercialization of medical devices.
In order to market a Medical Device, the MDR complies with ensuring safety, clinical performance, traceability, and post-market control throughout the entire device life cycle.
As a matter of fact, nowadays manufacturers operate within a single, integrated regulatory ecosystem, where scientific evidence, toxicological evaluation, risk management, and regulatory strategy must be aligned from early development through market surveillance.
Let’s dive into it to understand how this regulation shaped the industry.
MDR: What are Manufacturers’ Expectations
The transition to MDR has greatly increased regulatory expectations, including:
- Strengthened oversight by Notified Bodies.
- Enhanced requirements concerning clinical evaluation.
- Increased emphasis on biological and toxicological evaluation.
- More comprehensive technical documentation.
- Reinforced post-market surveillance and vigilance.
As a result, regulatory compliance is no longer a one-time activity but a continuous and proactive process.
Medical Device Commercialization
Within the MDR framework, medical device commercialization can no longer be considered the final step of product development.
Incorporating regulatory requirements, such as the biological evaluation specified by the international standard ISO 10993, into the early stages of the design and development process, enables the manufacturer’s company to:
- Minimize compliance failures.
- Avoid delayed certification.
- Reduce time to market.
- Turn compliance into a strategic competitive advantage.
With the ISO 10993-1:2025 update, new risk-based approaches have been introduced, strengthening the integration between:
- Biological evaluation.
- Toxicological evaluation.
- Clinical data.
- Risk management.
Understanding the impact of these changes is essential for both newly developed devices and those that are already in the market.
How MDR Consulting is supporting Manufacturers
The increasing complexity of MDR requires the intervention of expert regulatory consulting services to shorten the time to market and avoid common mistakes. Chemsafe experts assist manufacturers in breaking down the rules into attainable processes related to scientific evidence and the evaluation of toxicity, and understanding which kind of claim best fits the product.
Claims, Feasibility, and Borderline Products: Preventing Delays and Reclassification
The definition of product claims is closely linked to the applicable regulatory framework.
Speaking of borderline products, once the boundaries between regulatory classifications become ambiguous, misclassification may cause issues such as delay in processing, reclassification, and further regulatory approval requests.
The structured regulatory feasibility report considers the following:
- Intended use/purpose.
- Mechanism of action.
- Context of use.
This analysis supports the identification of regulatory-compliant and scientifically justifiable, supported by appropriate toxicological and biological evaluation, in full alignment with MDR requirements.
Our MDR Consulting Solutions
How can you always be compliant? Continuous compliance might be challenging to achieve as it requires:
- Constant updates to be aligned with the normative requirements and gap analysis.
- Monitoring of regulatory developments.
- Using a proactive approach to risk management.
We offer MDR consulting services to manufacturers, startups, and Small and Medium Enterprises (SMEs) across the entire device life cycle, with dedicated regulatory expertise.
In SMEs, our role also includes acting as Person Responsible for Regulatory Compliance (PRRC), for assisting firms in:
- Reducing their internal regulatory burden.
- Strengthen scientific and toxicological documentation.
- Accelerate market access in a safe and compliant manner.
Contact us to discover more about our Medical Device services!
